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Abstract: Azelastine nasal spray (Allergodil®, Lastin®, Aﬂ  uon®; Meda AB, Stockholm, Sweden) 
is a fast-acting, efﬁ  cacious and well-tolerated H1-receptor antagonist for the treatment of 
rhinitis. In addition it also has mast-cell stabilizing and anti-inﬂ  ammatory properties, reducing 
the concentration of leukotrienes, kinins and platelet activating factor in vitro and in vivo, as 
well as inﬂ  ammatory cell migration in rhinitis patients. Well-controlled studies in patients with 
seasonal allergic rhinitis (SAR), perennial rhinitis (PR) or vasomotor rhinitis (VMR) conﬁ  rm 
that azelastine nasal spray has a rapid onset of action, and improves nasal symptoms associated 
with rhinitis such as nasal congestion and post-nasal drip. Azelastine nasal spray is effective 
at the lower dose of 1 spray as well at a dose of 2 sprays per nostril twice daily, but with an 
improved tolerability proﬁ  le compared to the 2-spray per nostril twice daily regimen. Compared 
with intranasal corticosteroids, azelastine nasal spray has a faster onset of action and a better 
safety proﬁ  le, showing at least comparable efﬁ  cacy with ﬂ  uticasone propionate (Flonase®; GSK, 
USA), and a superior efﬁ  cacy to mometasone furoate (Nasonex®; Schering Plough, USA). In 
combination with ﬂ  uticasone propionate, azelastine nasal spray exhibits greater efﬁ  cacy than 
either agent used alone, and this combination may provide beneﬁ  t for patients with difﬁ  cult to 
treat seasonal allergic rhinitis. In addition, azelastine nasal spray can be used on an as-needed 
basis without compromising clinical efﬁ  cacy. Compared with oral antihistamines, azelastine 
nasal spray also demonstrates superior efﬁ  cacy and a more rapid onset of action, and is effective 
even in patients who did not respond to previous oral antihistamine therapy. Unlike most oral 
antihistamines, azelastine nasal spray is effective in alleviating nasal congestion, a particularly 
bothersome symptom for rhinitis sufferers. Azelastine nasal spray is well tolerated in both adults 
and children with allergic rhinitis. Bitter taste which seems to be associated with incorrect 
dosing technique is the most common side effect reported by patients, but this problem can be 
minimized by correct dosing technique.
Keywords: azelastine nasal spray, rhinitis, intranasal corticosteroids, oral antihistamines, 
seasonal allergic rhinitis
Introduction
Rhinitis is an inflammatory disease of the upper airways, affecting approximately 
58 million people only in the United States alone (Settipane 2001) and its prevalence is 
increasing. The cost of the disease is signiﬁ  cant with between US$2 and US$5 billion 
incurred annually in both direct and indirect costs (Ray et al 1999; Reed et al 2004). In 
the US, the number of lost workdays is estimated as approximately 3.5 million a year 
(Mahr and Sheth 2005). It can be classiﬁ  ed as allergic, non-allergic or mixed upper 
respiratory disorder (Berstein 2007). It is classiﬁ  ed as allergic if symptoms occur in 
association with a speciﬁ  c IgE-mediated response; as non-allergic if symptoms are 
induced by irritant triggers, but without an IgE-mediated response; and as of mixed 
etiology if IgE-mediated responses occur in conjunction with symptoms induced 
by both allergens and non-allergic irritant triggers. Allergic rhinitis (AR) is further 
classiﬁ  ed as seasonal or perennial (Dykewicz et al 1998). Seasonal allergic rhinitis Therapeutics and Clinical Risk Management 2008:4(5) 1010
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(SAR) symptoms are induced by exposure to pollens from 
trees, grass, weeds or seasonal mould spores, whilst peren-
nial rhinitis (PR) is associated with environmental allergens 
which are generally present on a year-round basis such as 
house dust, animal dander and insect droppings (Dykewicz 
et al 1998). In contrast, the “Allergic Rhinitis and its Impact 
on Asthma (ARIA) guidelines” recommend a classiﬁ  cation 
in intermittent allergic rhinitis and persistent allergic rhinitis 
according to the frequency and persistence of symptoms 
(Bousquet et al 2001).
Symptoms of SAR include nasal congestion, runny nose, 
nasal and nasopharyngeal itching, ear symptoms, sneezing 
and ocular symptoms in many patients, including itchy and 
watery eyes (Bielory and Ambrosio 2002). The symptoms 
of sneezing, itching and rhinorrhea are less common with 
PR (Economides and Kaliner 2002). As many as half of all 
patients diagnosed with rhinitis have non-allergic disease 
(sometimes called vasomotor rhinitis [VMR]) where an 
allergic component cannot be identiﬁ  ed (Dykewicz et al 
1998). Symptoms are often induced by irritant triggers such 
as tobacco smoke, strong odors and temperature and pres-
sure changes (Devyani and Corey 2004). The symptoms of 
VMR are similar to those of AR (Devyani and Corey 2004). 
To further complicate rhinitis classiﬁ  cation, as many as half 
of all patients with AR are also sensitive to non-allergic 
triggers; a condition referred to as mixed rhinitis (Settipane 
and Settipane 2002; Liberman et al 2005). Symptoms of 
rhinitis can have a major impact on patients’ quality of life 
(QoL) by interfering with sleep which causes fatigue, and 
impairing daily activities and cognitive function (Dykewicz 
et al 1998). Patients often complain of an inability to 
concentrate, and in the case of SAR often avoid outdoor 
activities in order to avoid exposure to symptom-inducing 
allergen(s). The Joint Task Force on Allergy Practice and 
Parameters advises that improving the negative impact on 
daily life in rhinitis patients deﬁ  nes successful treatment as 
much as providing symptom relief (Dykewicz et al 1998). 
Indeed, Juniper (1997) recommends that for most patients 
with rhinitis, improving patient well-being and QoL should 
be the primary goal of treatment.
Treatment guidelines from the Joint Task Force and WHO 
recommend that antihistamines, both topical (eg, azelastine 
[Allergodil®; Meda AB, Stockholm, Sweden]) and oral 
second-generation (eg, loratadine [Claritin®, Schering Plough, 
USA], desloratadine [Clarinex®; Schering Plough, USA], 
fexofenadine [Allegra®; Sanoﬁ   Aventis, USA] or cetirizine 
[Zyrtec®; Pﬁ  zer, USA], and levocetirizine [Xyzall®; UCB, 
EU]) be used as ﬁ  rst-line therapy for AR (Dykewicz et al 1998; 
Bousquet et al 2001). Intranasal corticosteroids (eg, ﬂ  uticasone 
propionate [Flonase®, GSK, USA], mometasone furoate 
[Nasonex®; Schering Plough, USA]) may also be considered 
as initial therapy for AR in patients with more severe symp-
toms, particularly nasal congestion [(Dykewicz et al 1998; 
LaForce 1999). The Allergic Rhinitis and its Impact on Asthma 
(ARIA) guidelines recommend a stepped approach to therapy 
based upon the frequency and severity of symptoms (Table 1) 
(Bousquet et al 2001). Interestingly, a recent US nationwide 
survey incorporating approximately 2500 adult allergy suf-
ferers, revealed that 66% were dissatisﬁ  ed with their current 
allergy medication due to lack of effectiveness (Anon 2006). 
Furthermore, more than two-thirds of primary care physicians 
reported patient dissatisfaction with therapy as the main reason 
for stopping or switching medications (Anon 2001). Clearly, 
effective therapies with a good safety proﬁ  le are needed to 
treat AR sufferers.
Azelastine
Azelastine nasal spray is a topically administered second-
generation antihistamine and selectively antagonizes the 
H1-receptor (Zechel et al 1981) being approximately tenfold 
more potent than chlorpheniramine in this regard (Casale 
1989). It has one of the fastest onsets of action (15 min 
with nasal spray and up to 3 min with eye drops) among the 
currently available rhinitis medications (Baumgarten et al 
1994; Greiff et al 1997). The effect of azelastine lasts at 
least 12 hours, thus allowing for a once or twice daily dosing 
regimen (Greiff et al 1997). It has proven efﬁ  cacy in treating 
both allergic and non-allergic rhinitis, and is the only pre-
scription antihistamine approved in the US, Portugal and the 
Netherlands for the treatment of both SAR (1996) and VMR 
(1999). In SAR patients azelastine therapy (two sprays per 
nostril twice daily), improved both total symptom and major 
symptom complex scores to a signiﬁ  cantly greater extent 
than placebo (McTavish and Sorkin 1989; Storms et al 1994; 
LaForce et al 1996; Ratner and Sacks 2007). Similarly, in PR 
patients, azelastine nasal spray signiﬁ  cantly improved sleep-
ing, reduced daytime somnolence and nasal congestion com-
pared with placebo (Golden et al 2000). Liberman et al (2005) 
were the ﬁ  rst to show that azelastine was also effective in the 
management of VMR and even in mixed rhinitis. Azelastine 
nasal spray signiﬁ  cantly (p   0.01) reduced the total VMR 
symptom score (TVRSS) compared with placebo after 21-day 
double-blind treatment, and was associated with clinical 
improvement in each symptom of the TVRSS (ie, rhinorrhea, 
sneezing, nasal congestion, and post-nasal drip). In a large 
open-label trial 4364 patients received azelastine nasal spray Therapeutics and Clinical Risk Management 2008:4(5) 1011
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(2 sprays per nostril twice daily) as monotherapy for 2 weeks. 
78% of VMR patients reported some or complete control of 
post-nasal drip which rose to 90% of SAR patients for the 
symptom of sneezing. Of patients reporting sleep difﬁ  culties 
or impaired daytime activities because of rhinitis symptoms, 
85% experienced improvements in these parameters with 
azelastine. Baseline sleep difﬁ  culties and impairment of 
daytime activities were signiﬁ  cant (p   0.01) predictors of a 
positive treatment effect with azelastine nasal spray. Female 
patients (p = 0.02), patients with SAR (p   0.01) and patients 
with SAR plus sensitivity to non-allergic triggers (p = 0.03) 
were identiﬁ  ed as being most likely to respond to azelastine 
nasal spray (Liberman et al 2005) Due to its rapid onset of 
action, azelastine nasal spray continues to control rhinitis 
symptoms when used on an as-needed basis (Ciprandi et al 
1997). This property of azelastine is discussed later. First 
marketed in the UK in 1991 for the treatment of both SAR 
and PR, it is currently available in more than 70 countries 
world-wide.
Mode of action
However, azelastine is more than just an anti-histamine. 
It exhibits a very fast and long-acting effect based on a 
triple mode of action, with anti-inﬂ  ammatory and mast cell 
stabilizing properties in addition to its anti-allergic effects 
(Bernstein 2007; Lee and Corren 2007). For example, azelas-
tine inhibits the activation of cultured mast cells and release 
of interleukin (IL)-6, tryptase, and histamine (Kempuraj 
et al 2002). It also reduces mediators of mast cell degranu-
lation such as leukotrienes which are involved in the late 
phase allergic response (Howarth 1997), in the nasal lavage 
ﬂ  uid of patients with rhinitis (Shin et al 1992). It does this 
possibly by reducing the production of leukotriene (LT)B4 
and LTC4, inhibiting phospholipase A2 and LTC4 synthase 
(Hamasaki et al 1996). Leukotrienes are associated with 
dilation of vessels, increased vascular permeability and 
edema which results in nasal congestion, mucus production 
and recruitment of inﬂ  ammatory cells (Golden et al 2006). 
Substance P and bradykinin concentrations which are formed 
in biological ﬂ  uids and tissues during inﬂ  ammation, are also 
reduced by azelastine (Shin et al 1992; Nieber et al 1993; 
Shinoda et al 1997). These agents are associated with the 
AR symptoms of nasal itching and sneezing, but may also 
contribute to the onset of non-allergic VMR symptoms. 
Other anti-inﬂ  ammatory properties of azelastine include 
inhibition of tumor necrosis factor alpha (TNFα) release 
Table 1 Summary of ARIA allergic rhinitis management guidelines
Rhinitis severity ARIA recommendation
Mild intermittent  • Oral/intranasal antihistamines OR
 • Decongestants (10 days maximum)
Moderate/severe intermittent  • Intranasal antihistamines
 • Oral antihistamines AND/OR
 • Decongestants
 • Intranasal corticosteroids
 • Cromones
Mild persistent  • Intranasal antihistamines
 • Oral antihistamines AND/OR
 • Decongestants
 • Intranasal corticosteroids
 • Cromones
A stepwise approach is advised with reassessment after 2 weeks. If symptoms 
are controlled and the patient is on intranasal corticosteroid, the dose should 
be reduced, but otherwise treatment continued. If symptoms persist and the 
patient is on antihistamines or cromones, a change should be made to an 
intranasal corticosteroid.
Moderate/severe persistent  • Intranasal corticosteroid (ﬁ  rst line treatment)
If symptoms are uncontrolled after 2–4 weeks, medication should be added 
depending on the persistent symptom, eg, add an antihistamine if the major 
symptom is rhinorrhea, pruitis, or sneezing, double the dose of intranasal 
steroid for persistent nasal blockage and add ipratropium for prominent 
complaint of rhinorrhea.Therapeutics and Clinical Risk Management 2008:4(5) 1012
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(Hide et al 1997; Matsuo and Takayama 1998), reduction 
of granulocyte macrophage colony-stimulating factor 
(GM-CSF) generation, as well as a reduction in the number 
of a range of inﬂ  ammatory cytokines including interleukin 
(IL)-1β, IL-6, IL-4 and IL-8 (Yoneda et al 1997; Ito et al 
1998; Beck et al 2000). These cytokines perpetuate the 
inﬂ  ammatory response (Settipane 2001). Finally, in SAR 
patients, azelastine nasal spray has been shown to lower 
neutrophil and eosinophil counts and decrease intercel-
lular adhesion molecule-1 (ICAM-1) expression on nasal 
epithelial cell surfaces in both the early and late phases of 
the allergic reaction (Ciprandi et al 1996). It also decreases 
free-radical production by human eosinophils and neutrophils 
(Busse et al 1989; Umeki 1992) and calcium inﬂ  ux induced 
by platelet-activating factor in vitro (Nakamura et al 1988; 
Morita et al 1993).
The use of a topical treatment has many advantages over 
a systemic treatment. Firstly, with a nasal spray, medication 
can be delivered directly to the site of allergic inﬂ  ammation. 
Secondly, the higher concentrations of antihistamines that 
can be achieved in the nasal mucosa by topical as opposed 
to oral administration should enhance the anti-allergic and 
potential anti-inﬂ  ammatory effects of these agents. Thirdly, a 
dose of 0.28 mg intranasally has a faster onset of action than 
a dose of 2.2 mg administrated orally (Horak et al 1994). And 
ﬁ  nally, with topical administration the risk of interaction with 
concomitant medication is minimized (Davies et al 1996) and 
the potential of systemic effects reduced.
Dosage
Recent results from 2 studies have shown that azelastine nasal 
spray at a dosage of 1 spray per nostril twice daily is effec-
tive and has a better tolerability proﬁ  le compared to 2 sprays 
per nostril twice daily in patients ( 12 years; n = 554) with 
moderate to severe SAR (Lumry et al 2007). The total nasal 
symptom score (TNSS) improved by 14.1% in study 1 and 
by 22.1% in study 2 with azelastine nasal spray (1 spray per 
nostril twice daily) compared with 4.5% and 12.0% with 
placebo in study 1 (p = 0.01) and 2 (p   0.01) respectively. 
This compares with a 24%–29% improvement in rhinitis 
symptoms scores with a 2-spray dosage of azelastine 
(Ratner et al 1994; Storms et al 1994; LaForce et al 1996). 
For individual symptoms, itchy nose, runny nose, sneezing, 
and nasal congestion were all signiﬁ  cantly improved after 
the 1-spray azelastine regimen compared with placebo. One 
spray per nostril twice daily of azelastine was also associ-
ated with signiﬁ  cant improvements in the Rhinitis Quality 
of Life Questionnaire (RQLQ) daily activity and nasal 
symptoms domains and patient global evaluations compared 
with placebo. In addition, the incidence of a bitter taste after 
azelastine application more than halved and the incidence of 
somnolence decreased almost 30 times in the 1-spray group 
versus the labeled incidence with the 2-spray regimen (Lumry 
et al 2007). Although an earlier study showed an improve-
ment in rhinitis symptoms versus placebo with azelastine 
1 spray per nostril twice daily, this improvement failed to 
reach statistical signiﬁ  cance. However, a global evaluation 
noted a signiﬁ  cant clinical improvement versus placebo 
(49%) in the 1-spray regimen (75%, p   0.001) as well as 
a 2-spray once daily (89%, p = 0.028) and a 2-spray twice 
daily regimen (83%, p   0.001) (Weiler et al 1994).
From these results one can conclude that a greater degree 
of effectiveness would be expected with two sprays per 
nostril twice daily. Although one spray per nostril twice daily 
may provide somewhat less efﬁ  cacy this is compensated for 
by an improved tolerability proﬁ  le compared with the 2-spray 
regimen. Therefore, the choice of dosage of azelastine nasal 
spray should be based on the severity and persistence of 
symptoms as well as the patient’s acceptance of the nasal 
spray (Bernstein 2007). For example, the 2-spray dose 
could be used as the starting dose for patients with severe 
symptoms of SAR, and either maintained or tapered to the 
1-spray dose as required. The 1-spray dose could be used as 
a starting dose in patients with mild-to-moderate symptoms, 
and if necessary the dose increased to 2 sprays per nostril 
twice daily if symptom control proved to be inadequate 
(Lumry et al 2007).
As-needed
Because azelastine starts working within 15 minutes of 
application investigators wondered how effective an as-needed 
regimen would be in controlling the symptoms of rhinitis 
(Ciprandi et al 1997). A randomized controlled study was car-
ried out in 30 patients sensitized to Parietaria pollen or grass. 
Patients were treated with the standard European dose of azelas-
tine (0.56 mg/day), half this dose (0.22 mg/day), or as-needed. 
Both groups who received the standard and half-standard 
doses showed an improvement in their rhinitis symptoms, 
with a concomitant reduction in markers of inﬂ  ammation, 
namely neutrophil and eosinophil counts as well as ICAM-1 
expression in nasal scrapings. However, patients who used 
azelastine nasal spray on an as-needed basis also showed an 
improvement in their rhinitis symptoms, but without a reduction 
in the markers of inﬂ  ammation. The results of this small study 
suggest that although regular treatment with azelastine is 
superior at controlling symptoms, as-needed therapy may be Therapeutics and Clinical Risk Management 2008:4(5) 1013
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useful in the treatment of clinical symptoms (Ciprandi et al 
1997). The use of azelastine nasal spray on an as-needed basis 
would be expected to improve drug tolerability and has impor-
tant implications for patient compliance. Another option is to 
use azelastine as-needed in addition to an oral antihistamine 
treatment on days with severe symptoms of SAR.
Comparisons with other agents 
used to treat rhinitis
The complexity of rhinitis as a disease and the multiple 
pathways involved in its pathophysiology mean that 
there are several classes of drugs available to treat it. These 
include intranasal corticosteroids, oral antihistamines, 
intranasal antihistamines and mast-cell stabilizers (eg, 
cromolyn compounds). A useful metric to compare each 
of these treatment modalities is the number needed to treat 
(NNT), which estimates the number of patients who must be 
treated with a particular drug in order to have one positive 
outcome. Obviously, drugs with low a NNT are considered 
more effective than those with a higher NNT. One report 
estimated the NNT range for oral antihistamines as 9–35, 3–6 
for intranasal corticosteroids, 5–6.3 for azelastine, and 4.6 for 
immunotherapy (Portnoy et al 2004). However, in that study 
the NNT was calculated using only a single trial for each 
drug, and so not all of the evidence was considered. A more 
recent meta-analysis systematically reviewed the efﬁ  cacy 
of azelastine nasal spray, in terms of global assessment of 
efﬁ  cacy, versus active comparators using NNTs as the out-
come measure (Lee and Pickard 2007). The active compara-
tors included beclomethasone (Beconase®; GSK, USA) and 
budesonide nasal sprays (Rhinocort®; Astra Zeneca, USA), 
loratadine, terfenadine (Seldane®; Sanoﬁ   Aventis, USA), 
cetirizine, ebastine (Kestine®), and levocabastine. Forty-six 
studies were initially identiﬁ  ed and 21 separate publications 
were included in the analysis. In 5 comparisons azelastine 
was more efﬁ  cacious than placebo with a summary NNT of 
5.0. No statistically signiﬁ  cant difference was found between 
azelastine nasal spray and the other treatments, including 
intranasal corticosteroids, in terms of their efﬁ  cacy in treating 
rhinitis. However, when the analysis was limited to studies in 
which an oral allergy treatment was the comparator, the point 
estimate of the pooled results favored azelastine nasal spray 
(Figure 1). The results were consistent across both SAR and 
nonallergic VMR, and across trials of different durations. 
Figure 1 Number needed to treat a global assessment of efﬁ  cacy as an outcome for azelastine nasal spray compared with oral agents for the treatment of allergic rhinitis. Reprinted 
with permission from Lee T, Pickard S. 2007. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmcotherapy, 27:852–9. Copyright © 2007 Pharmcotherapy 
Publications.
Abbreviations: CI, conﬁ  dence interval; NNT, number needed to treat.
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The risk difference would have been even more favourable 
for azelastine if only results for azelastine at a dose of 
1.12 mg/day were included in the analysis, but the small 
number of studies available for the meta-analysis precluded 
that stratiﬁ  cation (Lee and Pickard 2007).
Comparisons with intranasal 
corticosteroids
Azelastine nasal spray is a non-steroidal treatment and has 
some advantages over intranasal corticosteroids in the treat-
ment of SAR, even though its anti-inﬂ  ammatory effect is not 
as strong (Wang et al 1997). It has a faster onset of action 
compared with intranasal corticosteroids (Berkowitz et al 
1999; Horak et al 2006), with at least comparable (in the 
case of intranasal ﬂ  uticasone propionate) or superior (in the 
case of intranasal mometasone furoate) efﬁ  cacy, and has a 
better safety proﬁ  le (Behncke et al 2006; Patel et al 2007). 
Like intranasal corticosteroids, azelastine is effective in 
treating the symptom of nasal congestion. Whereas intrana-
sal corticosteroid therapy should begin before the onset of 
symptoms in order to obtain optimal beneﬁ  t from therapy 
antihistamines can also be taken on an as needed basis. 
But in contrast to intranasal corticosteroids azelastine may 
induce a bitter taste and nasal burning after application.
Azelastine versus mometasone furoate
Azelastine nasal spray is superior to the topical corticosteroid 
mometasone nasal spray in reducing nasal symptoms 
(Patel et al 2007). Patients with a history of SAR and symp-
tomatic while exposed to ragweed pollen in an environmental 
exposure chamber (EEC) were randomized to 2 sprays per 
nostril of azelastine nasal spray (137 μg/spray; n = 150), 
mometasone nasal spray (50 μg/spray; n = 150), or placebo. 
At 15 minutes after administration of study drugs, azelastine 
nasal spray signiﬁ  cantly reduced the TNSS from baseline 
by 29.5% compared with 12.3% with placebo (p   0.001) 
and this signiﬁ  cant superiority of azelastine over placebo 
persisted at each time point throughout the 8-hour allergen 
exposure (Figure 2). At 8-hour post-allergen challenge, 
azelastine had reduced the TNSS by 33.9% from baseline 
versus 18.6% with placebo. Conversely, mometasone furoate 
nasal spray did not signiﬁ  cantly reduce the TNSS from base-
line compared with placebo at any time point (p   0.09), 
and azelastine nasal spray was signiﬁ  cantly more effective 
than mometasone at each time point during the 8-hour study 
period (p   0.001; Figure 2) (Patel et al 2007). A previously 
published study has shown a 12- to 72-hour onset of action 
for mometasone (Berkowitz et al 1999) which would 
explain why mometasone did not signiﬁ  cantly improve 
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Figure 2 Onset of action of azelastine hydrochloride nasal spray in relieving nasal symptoms of seasonal allergic rhinitis. *p   0.001 azelastine vs placebo; *p   0.001 azelas-
tine vs mometasone; mometasone vs placebo = not signiﬁ  cant. Reprinted with permission from Patel P, D’Andrea C, Sacks HJ. 2007. Onset of action of azelastine nasal spray 
compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol, 21:499–503. 
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SAR symptoms compared to placebo within 8 hours after 
allergen exposure. An online survey by the American College 
of Allergy, Asthma and Immunology showed that 77% of 
allergists and 69% of primary care physicians thought rapid 
onset of action was an essential element of therapy (Physician 
Survey 2001). A rapid onset of action within 15 minutes, as 
shown with azelastine nasal spray, may enhance compliance 
with therapy.
Azelastine versus ﬂ  uticasone propionate
A study in geriatric patients with allergic or non-allergic 
rhinitis showed that azelastine nasal spray (2 sprays per 
nostril twice daily; 1.1 mg) was just as effective as ﬂ  uti-
casone propionate nasal spray 2 sprays per nostril daily; 
200 μg) at improving patients’ RQLQ scores (Figure 3) 
and rhinitis symptoms (Figure 4) (Behncke et al 2006). 
Azelastine nasal spray and oral antihistamines are often 
used concurrently with an intranasal corticosteroid spray 
in patients with difﬁ  cult to treat rhinitis symptoms. Several 
studies with oral antihistamines in combination with intra-
nasal corticosteroids showed no increased clinical beneﬁ  t 
with these drugs in combination (Weiner et al 1998; Nielsen 
and Dahl 2003). However, a recent proof-of-concept study 
showed that azelastine nasal spray and ﬂ  uticasone nasal 
spray in combination provided a substantial therapeutic 
beneﬁ  t for patients with SAR compared with therapy 
with either agent alone (Ratner and Sacks 2007). Patients 
were randomized to receive either azelastine nasal spray 
(2 sprays per nostril twice daily), ﬂ  uticasone nasal spray 
(2 sprays per nostril twice daily), or both agents together 
(same dosage). All three groups had statistically signiﬁ  -
cant (p   0.01) improvement from baseline in TNSS after 
2 weeks’ treatment, but the improvement was signiﬁ  cant 
(p   0.05) with the combination regimen (38%) versus 
either agent alone (azelastine: 25%; ﬂ  uticasone: 27%) 
(Ratner and Sacks 2007).
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Figure 3 Effect of azelastine nasal spray or ﬂ  uticasone propionate nasal spray on Rhinitis Quality of Life Questionnaire (RQLQ) scores in geriatric patients with either allergic 
or non-allergic rhinitis. Reprinted with permission from Behncke VB, Alemar GO, Kaufman DA, et al 2006.   Azelastine nasal spray and ﬂ  uticasone nasal spray in the treatment 
of geriatric patients with rhinitis. J Allergy Clin Immunol, 117:263. Copyright © 2006 Elsevier.
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Comparisons with oral antihistamines
Well-controlled studies in patients with rhinitis have shown 
that azelastine nasal spray demonstrates superior efﬁ  cacy and 
a more rapid onset of action compared to oral antihistamines 
(McNeely and Wiseman 1998; Corren et al 2005; Berger et al 
2006; Horak et al 2006; Meltzer and Sacks 2006; Sher and 
Sacks 2006). Azelastine is a potent drug and has been shown 
to be effective in patients suffering from rhinitis who have not 
responded to previous oral antihistamine therapy (Berger and 
White 2003; LaForce et al 2004). Additionally, it signiﬁ  cantly 
reduces nasal congestion (Herman et al 1997), a particularly 
bothersome symptom for rhinitis sufferers. Unlike some of the 
earlier antihistamines, topical application of azelastine produces 
very low plasma concentrations of the drug which reduces 
the sedative potential. Indeed, compared with cetirizine and 
loratadine, azelastine actually increased alertness in patients 
with seasonal or perennial rhinitis (Spaeth et al 1996).
Azelastine versus desloratadine
Desloratadine is a new anti-histamine tablet. In contrast to 
antihistamines of earlier generations, these drugs are thought 
to noticeably reduce nasal congestion (McClellan and Jarvis 
2001; Horak et al 2002b; Horak et al 2003), are non-sedating 
and do not cause cardiac side-effects. A recently published 
study was the ﬁ  rst to assess the efﬁ  cacy and onset of action 
of azelastine nasal spray (one spray per nostril) compared 
to desloratadine tablets (5 mg) in patients with SAR (Horak 
et al 2006). Results showed that azelastine nasal spray was 
signiﬁ  cantly better than desloratadine tablets in reducing 
the symptoms of SAR including ‘nasal congestion’ induced 
by allergen challenge in the Vienna Challenge Chamber 
(VCC). Both azelastine nasal spray and desloratadine tablets 
signiﬁ  cantly (p   0.001) reduced the Major Nasal Symptom 
Score (MNSS; deﬁ  ned as the sum of scores of sneezing, 
rhinorrhea and nasal itching) compared to placebo (Figure 5) 
(Horak et al 2006), with azelastine signiﬁ  cantly (p = 0.005) 
superior to desloratadine in this regard (Figure 5). In addi-
tion, the onset of action of azelastine nasal spray was 15 min. 
compared with 150 min. for desloratadine tablets. Regarding 
desloratadine tablets, the onset of action of 150 min reported 
by Horak et al (2006) was notably longer than that previously 
described (Horak et al 2002a). This may have been due to 
the encapsulation of desloratadine tablets for the purpose 
of blinding.
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The mean 4- to 6-hour change in TNSS, which comprised 
a score for nasal congestion, were consistent with those 
for MNSS. The largest improvement with azelastine was 
observed for nasal itching followed by sneezing, rhinorrhea 
and nasal congestion (Figure 6) (Horak et al 2006). In fact, 
azelastine nasal spray was superior to desloratadine tablets 
at alleviating nasal congestion when comparing absolute 
scores at the end of the challenge. This result was unexpected 
since to date, antihistamines have been found to have little 
decongestant activity, whereas reduction of nasal congestion 
is one of the main clinical advantages of third-generation 
anti-histamines (Horak and Stübner 2002; Murdoch et al 
2003). Signiﬁ  cant decongestant activity has previously been 
reported for azelastine nasal spray, but only at the higher 
dosage of  2 sprays per nostril (Thomas et al 1992). Therefore, 
these results suggest that azelastine at a dosage of 1 spray 
per nostril is just as effective as 2 sprays. However, one 
should be reminded that the improvement in nasal congestion 
following azelastine therapy is a subjective one, and further 
objective studies, measuring nasal ﬂ  ow or nasal resistance, 
are required to conﬁ  rm these ﬁ  ndings.
Azelastine versus cetirizine
Cetirizine hydrochloride is an oral second-generation anti-
histamine indicated for the treatment of SAR and PR. It 
also has demonstrated inhibitory effects on other mediators 
of inﬂ  ammation including leukotrienes (Cheria-Sammari 
et al 1995), prostaglandins (Charlesworth et al 1989), 
ICAM-1 expression, and eosinophil chemotaxis (Ciprandi 
et al 1995). The ﬁ  rst Azelastine Cetirizine Trial (ACT 1) 
carried out in the autumn of 2004, examined the effective-
ness and tolerability of azelastine (2 sprays per nostril) and 
cetirizine tablets (10 mg once daily) in 307 patients with 
moderate to severe SAR (Corren et al 2005). During the 
2-week double-blind treatment period, azelastine nasal 
spray signiﬁ  cantly (p = 0.02) improved the overall TNSS 
compared with cetirizine. All four symptom components 
of the TNSS were improved after azelastine therapy, with 
a signiﬁ  cantly greater improvement versus cetirizine for 
rhinorrhea (p = 0.003). Differences in the TNSS between 
azelastine nasal spray and cetirizine were sustained through-
out the study period and became more evident as the study 
progressed, with statistically signiﬁ  cant differences favoring 
azelastine nasal spray on study days 8 through 14. In addition, 
compared with cetirizine, azelastine nasal spray signiﬁ  cantly 
(p = 0.049) improved patients’ HRQoL as assessed by the 
RQLQ (Corren et al 2005).
More recently, two 2-week, double-blind, multi-center 
studies were conducted which compared the efﬁ  cacy and safety 
of azelastine nasal spray (2 sprays/nostril twice daily) with 
oral cetirizine (10 mg daily) in the treatment of patients with 
moderate to severe SAR (Sher and Sacks 2006). A combined 
analysis of results showed that azelastine nasal spray signiﬁ  -
cantly improved the TNSS (p   0.001) and each of the four 
individual symptoms of the TNSS (p   0.01) compared with 
cetirizine. Patients in the azelastine spray group experienced 
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an improvement in TNSS of 32.5% compared with 24.6% for 
those patients taking oral cetirizine. The most common side 
effect reported by patients in the azelastine group was bitter 
taste (5.7%). Somnolence was reported by 1.5% of patients 
taking cetirizine (Sher and Sacks 2006).
In addition to nasal symptoms, patients with SAR can 
experience impairment in HRQoL. Two 2-week, double-blind, 
multicenter studies were conducted during autumn 2004 and 
spring 2005 comparing the improvement with azelastine nasal 
spray (2 sprays per nostril twice daily) versus cetirizine (10 mg 
daily) on symptoms and HRQoL in SAR patients (Meltzer 
and Sacks 2006). Results from these studies revealed that 
azelastine nasal spray improved the overall RQLQ score to a 
signiﬁ  cantly (p   0.05) greater degree than cetirizine tablets. 
When results from both studies were pooled, the combined 
analysis conﬁ  rmed the signiﬁ  cant superiority of azelastine 
spray both in terms of the overall RQLQ score (p   0.001) 
as well as each RQLQ domain (p   0.03) including the nasal 
symptoms domain (p   0.001). More patients in the azelastine 
nasal spray group experienced a clinically important improve-
ment from baseline in HRQoL (ie,  2 units on the 0–6 rating 
scale) compared with patients in the cetirizine group (35% vs 
20% respectively) (Meltzer and Sacks 2006).
Berger et al (2006) also showed that azelastine nasal spray 
(2 sprays per nostril) and oral cetirizine (10 mg once daily) 
effectively treated nasal symptoms in patients with SAR 
(n = 360). Rapid relief of rhinitis symptoms was evident in 
both groups at the ﬁ  rst evaluation after initial administration 
and continued during the 14 study days, with the azelastine 
patients showing the greatest degree of improvement during 
the second week of treatment. Improvements in the TNSS 
and individual symptoms favored azelastine over cetirizine 
(Figure 7), with signiﬁ  cant differences for nasal congestion 
(p = 0.049) and sneezing (p = 0.01). Azelastine nasal spray 
improved TNSS by a mean of 4.6 (23.9%) compared with 
3.9 (19.6%) with cetirizine. The positive effect of azelastine 
nasal spray on congestion was observed despite the fact that 
the cetirizine group had the added beneﬁ  t of daily use of a 
placebo saline spray. Azelastine nasal spray also signiﬁ  cantly 
improved the RQLQ overall (p = 0.002) and individual 
domain (p   0.05) scores compared with cetirizine (Berger 
et al 2006). Although oral cetirizine signiﬁ  cantly improved 
RQLQ scores, patients treated with azelastine nasal spray 
reported additional statistically signiﬁ  cant improvement 
beyond that reported with cetirizine for each individual RQLQ 
domain including activities, sleep, non-nose/non-eye symp-
toms, practical problems, nasal symptoms, eye symptoms, 
and emotions (Figure 8). Although it is often assumed that 
patients prefer oral medications to sprays in both the ACT I 
and ACTII trials, patients reported superior improvements 
in QoL variables with azelastine nasal spray compared with 
oral cetirizine (Corren et al 2005).
MNSS Rhinorrhea Nasal Itching Sneezing Nasal Congestion
0
1
2
3
4
Azelastine
Desloratadine
Placebo
A
b
s
o
l
u
t
e
 
I
m
p
r
o
v
e
m
e
n
t
f
r
o
m
b
a
s
e
l
i
n
e
(
1
2
0
 
m
i
n
 
s
c
o
r
e
–
3
6
0
 
m
i
n
 
s
c
o
r
e
)
Figure 6 Major nasal symptom and mean nasal symptom scores after administration of azelastine nasal spray (1 spray per nostril), desloratadine (5 mg) or placebo in patients 
with SAR: absolute changes of last value (6 hours after the start of challenge) compared to predose (ie, 2 hours after the start of the challenge). Reprinted with permission 
from Horak F, Zieglmayer UP, Zidglmayer R, et al 2006.   Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study 
of onset of action and efﬁ  cacy. Curr Med Res Opion, 22:151–7. Copyright © 2006 LibraPharm.Therapeutics and Clinical Risk Management 2008:4(5) 1019
Azelastine nasal spray
Azelastine nasal spray and cetirizine were well tolerated 
in this study (Berger et al 2006). Relatively high incidences 
of somnolence and bitter taste have been previously reported 
in early trials with azelastine nasal spray (Meltzer et al 1994; 
Storms et al 1994; Weiler et al 1994; LaForce et al 2004; 
Ratner and Sacks 2007). However, subsequent trials in 
patients with VMR (Banov and Liberman 2001) and post-
marketing studies in patients who remained symptomatic 
after treatment with loratadine (Berger and White 2003) 
or fexofenadine (LaForce 1999) reported somnolence rates 
with azelastine nasal spray that were similar to those with 
placebo.
Non-responders
As many as 20% of all AR patients do not respond to 
oral H1 blockers at all (Berger and White 2003). Two 
studies assessed the efﬁ  cacy of azelastine in patients 
with moderate-to-severe SAR who had an unsatisfactory 
response to oral second generation antihistamines (Berger 
and White 2003; LaForce et al 2004). The ﬁ  rst study 
comprised 435 patients who had a sub-optimal response 
to loratadine and showed that both azelastine monotherapy 
and azelastine plus loratadine signiﬁ  cantly (p   0.001) 
improved total symptoms compared with placebo (Berger 
and White 2003). The second study comprised 334 patients 
who had failed to response to 1 week treatment with 
fexofenadine. Similar results were obtained, in that patients 
in both the azelastine and combination groups showed 
signiﬁ  cant (p   0.01) improvement in their symptoms 
compared with placebo.
Azelastine versus other intranasal 
antihistamines
Azelastine versus levocabastine
Levocabastine is a potent and selective histamine H1-receptor 
antagonist. Previous limited data indicated equivalent 
efﬁ  cacy of levocabastine to that of oral loratadine, oral 
cetirizine or azelastine nasal spray (Noble and McTavish 
1995). More recently, the efficacy and tolerability of 
azelastine nasal spray (1.12 mg, 2 sprays twice daily) was 
shown to be statistically superior to that of topical intranasal 
levocabastine (0.4 mg, 2 sprays twice daily) in a 4-week, 
double-blind, parallel-group study in 180 patients (Falser 
et al 2001). Results showed that azelastine was signiﬁ  cantly 
(p   0.001) superior at reducing both morning and evening 
nasal symptoms compared to levocabastine, and was judged 
to be signiﬁ  cantly (p   0.007) more efﬁ  cacious in a global 
evaluation by the investigator. Global efﬁ  cacy was judged by 
physicians as either ‘very good’ or ‘good’ for 90% of azelas-
tine patients compared to 74% of the levocabastine group; 
moreover, 92% of azelastine patients judged the treatment 
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as either ‘good’ or ‘very good’ compared with just 76% of 
levocabastine patients (Falser et al 2001).
Safety and tolerability
The advantages of intranasal delivery include lower risk 
of systemic side effects and drug interactions (Salib and 
Howarth 2003). In controlled studies, azelastine nasal spray 
was well-tolerated for treatment durations up to 4 weeks in 
both adults and children ( 12 years) (Storms et al 1994; 
Meltzer et al 1994; Ratner et al 1994; Weiler et al 1994; 
LaForce et al 1996). Bitter taste, headache, somnolence and 
nasal burning were the most frequently reported adverse 
events, but most of these were mild or moderate in nature. 
These studies reported a greater incidence of somnolence 
compared with placebo (11.5% vs 5.4%, p   0.05). How-
ever, the incidence of somnolence between azelastine- and 
placebo-treated patients (3.2% vs 1.0%) did not differ in 
VMR studies (Banov and Liberman 2001). Post-marketing 
surveillance studies also reported a similar degree of 
somnolence (approx 2%) in both azelastine and placebo 
groups (Berger and White 2003; LaForce et al 2004; 
Corren et al 2005; Berger et al 2006). The lower incidence 
of azelastine-related adverse events in later trials is most 
likely due to correct dosing technique, when the drug is 
administered without tipping back the head or deeply 
inhaling the spray, both of which would increase systemic 
absorption and could result in bitter taste and somnolence. 
As the incidence of somnolence whilst using azelastine 
nasal spray has been reported to be greater than placebo 
in certain studies, US prescribing recommendations warn 
against concurrent use of alcohol and/or other CNS sup-
pressants. However, to date no studies have been designed 
to assess speciﬁ  cally the effects of azelastine nasal spray 
on the CNS in humans.
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